Anticancer and anti-inflammatory properties of ganoderma lucidum extract effects on melanoma and triple-negative breast cancer treatment

Nutrients

Volumn 9, Issue 3, 2017, Pages

  Barbieri, Antonio ^a   Quagliariello, Vincenzo ^a,b   Del Vecchio, Vitale ^a   Falco, Michela ^a   Luciano, Antonio ^a   Amruthraj, Nagoth Joseph ^c   Nasti, Guglielmo ^a,b   Ottaiano, Alessandro ^a   Berretta, Massimiliano ^b,d   Iaffaioli, Rosario Vincenzo ^a,b   Arra, Claudio ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b Association for Multidisciplinary Studies in Oncology and Mediterranean Diet   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

^d CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

Breast cancer; Cell viability; Curcumin; Cytokines; Ganoderma lucidum; Inflammation; Melanoma

Indexed keywords

GANODERMA LUCIDUM EXTRACT; GELATINASE A; GELATINASE B; INTERLEUKIN 6; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; MELANOMA; MTT ASSAY; NONHUMAN; TRIPLE NEGATIVE BREAST CANCER; WOUND HEALING; ANIMAL; C57BL MOUSE; CHEMISTRY; DRUG EFFECTS; GANODERMA LUCIDUM; METABOLISM; MOUSE; PATHOLOGY; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR CELL LINE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; INTERLEUKIN-6; INTERLEUKIN-8; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MELANOMA; MICE; MICE, INBRED C57BL; REISHI; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 85014373266     PISSN: None     EISSN: 20726643     Source Type: Journal    
DOI: 10.3390/nu9030210     Document Type: Article

References (25)

1. Russell, R.; Paterson, M. Ganoderma—A therapeutic fungal biofactory. Phytochemistry 2006, 67, 1985–2001.
2. Kao, C.H.J.; Jesuthasan, A.C.; Bishop, K.S.; Glucina, M.P.; Ferguson, L.P. Anti-cancer activities of Ganoderma lucidum: Active ingredients and pathways. Funct. Foods Health Dis. 2013, 3, 48–65.
3. Lin, Z.B. Cellular and molecular mechanisms of immuno-modulation by Ganoderma lucidum. J. Pharmacol. Sci. 2005, 99, 144–153 [CrossRef] [PubMed]
4. Ko, H.H.; Hung, C.F.; Wang, J.P.; Lin, C.N. Antiinflammatory triterpenoids and steroids from Ganoderma lucidum and GANODERMA tsugae. Phytochemistry 2008, 69, 234–239 [CrossRef] [PubMed]
5. Zhang, W.; Tao, J.; Yang, X.; Yang, Z.; Zhang, L.; Liu, H.; Wu, K.; Wu, J. Antiviral effects of two Ganoderma lucidum triterpenoids against enterovirus 71 infection. Biochem. Biophys. Res. Commun. 2014, 449, 307–312 [CrossRef] [PubMed]
6. Sanodiya, B.S.; Thakur, G.S.; Baghel, R.K.; Prasad, G.B.; Bisen, P.S. Ganoderma lucidum: A potent pharmacological macrofungus. Curr. Pharm. Biotechnol. 2009, 10, 717–742 [CrossRef] [PubMed]
7. Kao, C.H.J.; Bishop, K.S.; Xu, Y.; Han, D.Y.; Murray, P.M.; Marlow, G.J.; Ferguson, L.R. Identification of Potential Anticancer Activities of Novel Ganoderma lucidum Extracts Using Gene Expression and Pathway Network Analysis. Genom. Insights 2016, 9, 1–16.
8. Bimonte, S.; Barbieri, A.; Leongito, M.; Piccirillo, M.; Giudice, A.; Pivonello, C.; de Angelis, C.; Granata, V.; Palaia, R.; Izzo, F. Curcumin AntiCancer Studies in Pancreatic Cancer. Nutrients 2016, 8, 433 [CrossRef] [PubMed]
9. Bimonte, S.; Barbieri, A.; Palma, G.; Rea, D.; Luciano, A.; D’Aiuto, M.; Arra, C.; Izzo, F. Dissecting the role of curcumin in tumour growth and angiogenesis in mouse model of human breast cancer. BioMed Res. Int. 2015 [CrossRef] [PubMed]
10. Bimonte, S.; Barbieri, A.; Palma, G.; Luciano, A.; Rea, D.; Arra, C. Curcumin inhibits tumor growth and angiogenesis in an orthotopic mouse model of human pancreatic cancer. BioMed Res. Int. 2013 [CrossRef] [PubMed]
11. Vecchione, R.; Quagliariello, V.; Calabria, D.; Calcagno, V.; de Luca, E.; Iaffaioli, R.V.; Netti, P.A. Curcumin bioavailability from oil in water nano-emulsions: In vitro and in vivo study on the dimensional, compositional and interactional dependence. J. Control. Release 2016, 233, 88–100 [CrossRef] [PubMed]
12. Shi, Z.; Yang, W.M.; Chen, L.P.; Yang, D.H.; Zhou, Q.; Zhu, J.; Chen, J.J.; Huang, R.C.; Chen, Z.S.; Huang, R.P. Enhanced chemosensitization in multidrug-resistant human breast cancer cells by inhibition of IL-6 and IL-8 production. Breast Cancer Res. Treat. 2012, 135, 737–747 [CrossRef] [PubMed]
13. Luo, Y.; Ellis, L.Z.; Dallaglio, K.; Takeda, M.; Robinson, W.A.; Robinson, S.E.; Liu, W.; Lewis, K.D.; McCarter, M.D.; Gonzalez, R.; et al. Side population cells from human melanoma tumors reveal diverse mechanisms for chemoresistance. J. Investig. Dermatol. 2012, 132, 2440–2450 [CrossRef] [PubMed]
14. Weng, C.J.; Yen, G.C. The in vitro and in vivo experimental evidences disclose the chemopreventive effects of Ganoderma lucidum on cancer invasion and metastasis. Clin. Exp. Metastasis 2010, 27, 361–369 [CrossRef] [PubMed]
15. Ruan, W.; Wei, Y.; Popovich, D.G. Distinct responses of cytotoxic Ganoderma lucidum triterpenoids in human carcinoma cells. Phytother. Res. 2015, 29, 1744–1752 [CrossRef] [PubMed]
16. Chen, H.S.; Tsai, Y.F.; Lin, S.; Lin, C.C.; Khoo, K.H.; Lin, C.H. Studies on the immuno-modulating and anti-tumor activities of Ganoderma lucidum (Reishi) polysaccharides. Bioorg. Med. Chem. 2004, 12, 5595–5601 [CrossRef] [PubMed]
17. Liang, Z.E.; Yi, Y.J.; Guo, Y.T.; Wang, R.C.; Hu, Q.L.; Xiong, X.Y. Inhibition of migration and induction of apoptosis in LoVo human colon cancer cells by polysaccharides from Ganoderma lucidum. Mol. Med. Rep. 2015, 12, 7629–7636 [CrossRef] [PubMed]
18. Hoejberg, L.; Bastholt, L.; Johansen, J.S.; Christensen, I.J.; Gehl, J.; Schmidt, H. Serum interleukin-6 as a prognostic biomarker in patients with metastatic melanoma. Melanoma Res. 2012, 22, 287–293 [CrossRef] [PubMed]
19. Dethlefsen, C.; Højfeldt, G.; Hojman, P. The role of intratumoral and systemic IL-6 in breast cancer. Breast Cancer Res. Treat. 2013, 138, 657–664 [CrossRef] [PubMed]
20. Salgado, R.; Junius, S.; Benoy, I.; Van Dam, P.; Vermeulen, P.; Van Marck, E.; Huget, P.; Dirix, L.Y. Circulating interleukin-6 predicts survival in patients with metastatic breast cancer. Int. J. Cancer 2003, 103, 642–646 [CrossRef] [PubMed]
21. Hoejberg, L.; Bastholt, L.; Schmidt, H. Interleukin-6 and melanoma. Melanoma Res. 2012, 22, 327–333 [CrossRef] [PubMed]
22. Gutman, M.; Even-Sapir, E.; Merimsky, O.; Trejo, L.; Klausner, J.M.; Lev-Chelouche, D. The role of interleukin-8 in the initiation and progression of human cutaneous melanoma. Anticancer Res. 2002, 22, 3395–3398 [PubMed]
23. Benoy, I.H.; Salgado, R.; van Dam, P.; Geboers, K.; van Marck, E.; Scharpé, S.; Vermeulen, P.B.; Dirix, L.Y. Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival. Clin. Cancer Res. 2004, 10, 7157–7162 [CrossRef] [PubMed]
24. Wang, H.H.; McIntosh, A.R.; Hasinoff, B.B.; MacNeil, B.; Rector, E.; Nance, D.M.; Orr, F.W. Regulation of B16F1 melanoma cell metastasis by inducible functions of the hepatic microvasculature. Eur. J. Cancer 2002, 38, 1261–1270 [CrossRef]
25. Ahmed, A.; Wang, J.H.; Redmond, H.P. Silencing of TLR4 increases tumor progression and lung metastasis in a murine model of breast cancer. Ann. Surg. Oncol. 2013, 20 (S3), S389–S396 [CrossRef] [PubMed]